Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Recruiting

Patients in this study will receive nivolumab in combination with the standard of care dose-adjusted EPOCH (etoposide, prednisone, vincristine, doxorubicin, cyclophosphamide) for six 21 day cycles. Patients will then have an autologous stem cell transplant or continue to receive maintenance therapy with nivolumab.

Study Type:        Interventional

Study Design:        

Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:        Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma                                                         

Condition:  Peripheral T-Cell Lymphoma                                      

Intervention:  

Drug: Nivolumab and EPOCH                           

Phase:  Phase 2

External Link:  https://clinicaltrials.gov/ct2/show/NCT03586999